Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Capital Leases (2023 - 2026)

bioAffinity Technologies has reported Capital Leases over the past 4 years, most recently at $514834.0 for Q1 2026.

  • Quarterly Capital Leases rose 53.27% to $514834.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $514834.0 through Mar 2026, up 53.27% year-over-year, with the annual reading at $532759.0 for FY2025, 19.87% up from the prior year.
  • Capital Leases was $514834.0 for Q1 2026 at bioAffinity Technologies, down from $532759.0 in the prior quarter.
  • Over five years, Capital Leases peaked at $929570.0 in Q3 2023 and troughed at $1998.0 in Q3 2025.
  • The 4-year median for Capital Leases is $532759.0 (2025), against an average of $502088.0.
  • Year-over-year, Capital Leases plummeted 99.63% in 2025 and then skyrocketed 53.27% in 2026.
  • A 4-year view of Capital Leases shows it stood at $835467.0 in 2023, then crashed by 46.8% to $444448.0 in 2024, then grew by 19.87% to $532759.0 in 2025, then dropped by 3.36% to $514834.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Capital Leases are $514834.0 (Q1 2026), $532759.0 (Q4 2025), and $1998.0 (Q3 2025).